{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:30:35Z","timestamp":1786116635412,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000894","name":"Spinal Muscular Atrophy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000894","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","award":["21GRO-PS48-0247"],"award-info":[{"award-number":["21GRO-PS48-0247"]}],"id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["MUR2426"],"award-info":[{"award-number":["MUR2426"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["MUR2021"],"award-info":[{"award-number":["MUR2021"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.expneurol.2026.115898","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:23:29Z","timestamp":1782491009000},"page":"115898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Persistent deficits in the motor unit following mono and dual administration of SMN up-regulators in the Smn\u03947 mouse model of spinal muscular atrophy"],"prefix":"10.1016","volume":"404","author":[{"given":"Inga","family":"Partlova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Comley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Haigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma Serena","family":"Tarodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.28476","article-title":"Evaluating the effects of nusinersen treatment in adults with spinal muscular atrophy using axonal excitability and mscanfit mune","volume":"72","author":"Alaamel","year":"2025","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.expneurol.2026.115898_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000164","article-title":"Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with Nusinersen","volume":"3","author":"Arnold","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.expneurol.2026.115898_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1368658","article-title":"Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy","volume":"15","author":"Bagga","year":"2024","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.expneurol.2026.115898_bb0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nmd.2011.09.007","article-title":"A critical SMN threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology","volume":"22","author":"Bowerman","year":"2012","journal-title":"Neuromuscul. Disord."},{"issue":"6179","key":"10.1016\/j.expneurol.2026.115898_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.1248523","article-title":"Optical control of muscle function by transplantation of stem cell\u2013derived motor neurons in mice","volume":"344","author":"Bryson","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2026.115898_bb0045","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88250.3","article-title":"An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of amyotrophic lateral sclerosis","volume":"12","author":"Bryson","year":"2024","journal-title":"eLife"},{"issue":"11","key":"10.1016\/j.expneurol.2026.115898_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103376","article-title":"Central synaptopathy is the most conserved feature of motor circuit pathology across spinal muscular atrophy mouse models","volume":"24","author":"Buettner","year":"2021","journal-title":"iScience"},{"issue":"18","key":"10.1016\/j.expneurol.2026.115898_bb0055","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/hmg\/ddac097","article-title":"Motor unit recovery following SMN restoration in mouse models of spinal muscular atrophy","volume":"31","author":"Comley","year":"2022","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115898_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1727-6","article-title":"Reduced p53 levels ameliorate neuromuscular junction loss without affecting motor neuron pathology in a mouse model of spinal muscular atrophy","volume":"10","author":"Courtney","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115898_bb0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115898_bb0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of Nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the nurture study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mus.20104","article-title":"Motor unit characteristics in healthy subjects and those with POSTPOLIOMYELITIS syndrome: a high-density surface EMG study","volume":"30","author":"Drost","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2026.115898_bb0085","article-title":"A battery of motor tests in a neonatal mouse model of cerebral palsy","volume":"117","author":"Feather-Schussler","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"18","key":"10.1016\/j.expneurol.2026.115898_bb0090","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.expneurol.2026.115898_bb0095","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for prenatal therapy of spinal muscular atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115898_bb0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0105","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","article-title":"High-dose Nusinersen for spinal muscular atrophy: a phase 3 randomized trial","volume":"32","author":"Finkel","year":"2026","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.expneurol.2026.115898_bb0110","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/biom12101524","article-title":"SMN is physiologically downregulated at wild-type motor nerve terminals but aggregates together with neurofilaments in SMA mouse models","volume":"12","author":"Franco-Espin","year":"2022","journal-title":"Biomolecules"},{"issue":"16","key":"10.1016\/j.expneurol.2026.115898_bb0115","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","article-title":"Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy","volume":"27","author":"Groen","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2026.115898_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115230","article-title":"Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy","volume":"389","author":"Hsieh","year":"2025","journal-title":"Exp. Neurol."},{"issue":"7367","key":"10.1016\/j.expneurol.2026.115898_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral smn restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.expneurol.2026.115898_bb0130","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.expneurol.2026.115898_bb0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI72017","article-title":"Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation","volume":"124","author":"Kariya","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with Nusinersen","volume":"92","author":"Kariyawasam","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006680","article-title":"Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases","volume":"13","author":"Kline","year":"2017","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115898_bb0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol. Clin."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2026.115898_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105488","article-title":"Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic \u22067SMA mice","volume":"159","author":"Kray","year":"2021","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115898_bb0165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/hmg\/ddae190","article-title":"Motor pool selectivity of neuromuscular degeneration in type I spinal muscular atrophy is conserved between human and mouse","volume":"34","author":"Lee","year":"2024","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddr453","article-title":"Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy","volume":"21","author":"Ling","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.expneurol.2026.115898_bb0180","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"18","key":"10.1016\/j.expneurol.2026.115898_bb0185","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115898_bb0190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115898_bb0195","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"10.1016\/j.expneurol.2026.115898_bb0200","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.nmd.2010.06.013","article-title":"Using mouse cranial muscles to investigate neuromuscular pathology in vivo","volume":"20","author":"Murray","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-015-0231-1","article-title":"Transcriptional profiling of differentially vulnerable motor neurons at pre-symptomatic stage in the SMN 2B\/\u2212 mouse model of spinal muscular atrophy","volume":"3","author":"Murray","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"8","key":"10.1016\/j.expneurol.2026.115898_bb0210","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1101\/gr.265017.120","article-title":"LCM-Seq reveals unique transcriptional adaptation mechanisms of resistant neurons and identifies protective pathways in spinal muscular atrophy","volume":"30","author":"Nichterwitz","year":"2020","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115898_bb0215","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"72","key":"10.1016\/j.expneurol.2026.115898_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.expneurol.2026.115898_bb0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2026.02.003","article-title":"Spinal muscular atrophy\u2014survivorship and care in a new therapeutic landscape","volume":"178","author":"Patel","year":"2026","journal-title":"Pediatr. Neurol."},{"issue":"17","key":"10.1016\/j.expneurol.2026.115898_bb0230","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.expneurol.2026.115898_bb0235","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1523\/JNEUROSCI.4496-09.2010","article-title":"Altered intracellular ca2+homeostasis in nerve terminals of severe spinal muscular atrophy mice","volume":"30","author":"Ruiz","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.expneurol.2026.115898_bb0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5535\/arm.240046","article-title":"Rehabilitation strategies for patients with spinal muscular atrophy in the era of disease-modifying therapy","volume":"48","author":"Shin","year":"2024","journal-title":"Ann. Rehabil. Med."},{"issue":"7","key":"10.1016\/j.expneurol.2026.115898_bb0245","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene Abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.expneurol.2026.115898_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052605","article-title":"Morphological characteristics of motor neurons do not determine their relative susceptibility to degeneration in a mouse model of severe spinal muscular atrophy","volume":"7","author":"Thomson","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mus.20259","article-title":"Post-poliomyelitis syndrome","volume":"31","author":"Trojan","year":"2005","journal-title":"Muscle Nerve"},{"issue":"22","key":"10.1016\/j.expneurol.2026.115898_bb0260","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1093\/hmg\/ddz188","article-title":"AAV9-STATHMIN1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy","volume":"28","author":"Villal\u00f3n","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.expneurol.2026.115898_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-022-00305-9","article-title":"Mouse models of SMA show divergent patterns of neuronal vulnerability and resilience","volume":"12","author":"Woschitz","year":"2022","journal-title":"Skelet. Muscle"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488626002633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488626002633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:13:25Z","timestamp":1786014805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488626002633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S0014488626002633"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.115898","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent deficits in the motor unit following mono and dual administration of SMN up-regulators in the Smn\u03947 mouse model of spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2026.115898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115898"}}